Cart
sales@molnova.com
Trotabresib
CAS No. 1706738-98-8
Trotabresib( —— )
Catalog No. M34836 CAS No. 1706738-98-8
Trotabresib (CC-90010) is an orally active inhibitor of BET and can be used in studies about advanced solid tumors.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 128 | Get Quote |
|
| 5MG | 188 | Get Quote |
|
| 10MG | 312 | Get Quote |
|
| 25MG | 512 | Get Quote |
|
| 50MG | 731 | Get Quote |
|
| 100MG | 963 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTrotabresib
-
NoteResearch use only, not for human use.
-
Brief DescriptionTrotabresib (CC-90010) is an orally active inhibitor of BET and can be used in studies about advanced solid tumors.
-
DescriptionCC-90010 (compound 1) is a reversible and orally active BET inhibitor. CC-90010 is applied in the study for advanced solid tumors.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorEpigenetic Reader Domain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1706738-98-8
-
Formula Weight383.46
-
Molecular FormulaC21H21NO4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (130.39 mM; Ultrasonic )
-
SMILESCn1cc(-c2cc(ccc2OCC2CC2)S(C)(=O)=O)c2ccccc2c1=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. CELGENE QUANTICEL RESEARCH, INC. PROCESS FOR THE PREPARATION OF BROMODOMAIN INHIBITOR. Patent. WO2020023438.
molnova catalog
related products
-
GSK8573
GSK8573 is an inactive control compound for GSK2801. GSK8573 has binding activity to BRD9 (Kd of 1.04 μM).
-
Alobresib
Alobresib is an inhibitor of BET bromodomain,is an antineoplastic drug candidate.
-
BY27
BY27, a potent and selective BET BD2 inhibitor (Ki: 3.1 nM) with anticancer activity, inhibits BD1/BD2 of BRD2, BRD3, BRD4, and BRDT, and suppresses tumor growth.
